cilgavimab

From Aaushi

Jump to navigation Jump to search

^[1]^[2]

Indications

used in combination with tixagevimab for prevention of Covid-19

* emergency use authorization

Dosage

cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial

Mechanism of action

monoclonal antibody specifically directed against the spike protein of SARS-CoV2

More general terms

monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)

References

↑ MedlinePlus: Tixagevimab and Cilgavimab https://medlineplus.gov/druginfo/meds/a621058.html
↑ HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA) Evusheld (tixagevimab) injection; (cilgavimab) injection, co-packaged for intramuscular use https://www.fda.gov/media/154701/download

Retrieved from "https://aaushi.info/w/index.php?title=A57459&oldid=1089734"

↑ Back to top